Seema Singh
Co-founder and Editor at The Ken
Not given up on Journalism, yet. Learning to lead, edit, write & report better. Co-founder, Editor & Writer @thekenweb. (Always hiring) Author: Mythbreaker
Articles
-
1 week ago |
the-ken.com | Seema Singh
Good morning [%first_name |Dear Reader%], When big ships turn, they displace a lot of water. And the Danish giant Novo Nordisk is making a sharp turn. It's phasing out insulin, the life-saving drug that has been in the market for over 40 years, to make way for newer, better, and more expensive products. In India, some 11 million diabetics are on insulin, and Novo commands 60% of the nearly Rs 5,000 crore market.
-
2 weeks ago |
the-ken.com | Seema Singh
Good morning [%first_name |Dear Reader%], Drones are flying everywhere. During the Pahalgam terrorist attack last week. In the Ukraine-Russia warfare escalation this week. For drug surveillance on the borders; over farmlands in the Indian hinterland. One company that's making the most of drone buzz-iness is Optiemus Infracom, a 31-year-old firm that distributes and assembles electronic devices.
-
1 month ago |
the-ken.com | Seema Singh
Good morning [%first_name |Dear Reader%], Pharma is spared but medical devices got the Trump sledgehammer. Like much of the Liberation Day calculus, hitting Indian medical devices with a 26% tariff makes little sense. India exported $715 million worth of medical devices to the US but imported a little over double that in FY24, per the newly constituted Exports Promotion Council for Medical Devices.
-
1 month ago |
tandfonline.com | Seema Singh
Advanced search Journal of the American Planning Association Latest Articles Submit an article Journal homepage Full Article Figures & data Citations Metrics Reprints & Permissions Read this article /doi/full/10.1080/01944363.2025.2476358?needAccess=true "City of Men: Masculinities and Everyday Morality on Public Transport." Journal of the American Planning Association, ahead-of-print(ahead-of-print), pp. 1–2 Log in via your institution Access through your institution Log in to Taylor &...
-
1 month ago |
the-ken.com | Seema Singh
Seema has over two decades of experience in journalism. Before starting The Ken, Seema wrote "Myth Breaker: Kiran Mazumdar-Shaw and the Story of Indian Biotech", published by HarperCollins in May 2016. Even with a trendy artificial intelligence tool, it'd be hard to gauge what India's AI Mission aims to achieve. It doesn't help that the technology is advancing at a weekly cadence, if not daily.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 3K
- Tweets
- 4K
- DMs Open
- No
Novo Nordisk and its two rival insulin giants are phasing out their insulin business in India. Biocon-Eris sees a windfall. But it's a humbling lesson in self-reliance for India. @sudeshna_ra & I write : https://t.co/rnmFsrSlXM https://t.co/7OzO3UHR0F
Why Zetwerk and others are channelling Nokia to dodge the new tariff trap. The global supply chain is repositioning. @ShristiAchar & I report https://t.co/vYCv3ZRrTv https://t.co/8ZaoNwp4h4
One of the three companies globally to show cell therapy results for dry AMD, an eye disorder affecting nearly 200 million globally, Bengaluru’s Eyestem is also eyeing a disruptive price. My story today: https://t.co/JxPTDEUqwu https://t.co/imTOLJimkW